Is TB-500 Legal in Maryland? Federal Rules, State Law, and How to Get It

HealthRX.com

The peptide has no clear federal path for compounding in Maryland

Print or save as PDF

See the public record for TB-500

  • FDA approval / none; no approved product in the United States, Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1]
  • FDA compounding lists / in none of the three interim-policy categories for state-licensed pharmacies; also absent from the outsourcing-facility list [2][3][4]
  • Safety-risk page / in the 'nominated but withdrawn' table, not the active Category 2 table [7]
  • Advisory committee / voted in favor of listing on July 23, 2026; advice only [8][5]
  • HHS draft policy / names TB-500 acetate for injection; draft and non-binding [5][6]
  • Sport / prohibited at all times under WADA S2.3 [9][10]
  • Human data / FDA found no article in which TB-500 was given to a person [1]

What TB-500 is

A synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, about 889 g/mol. It is not full-length thymosin beta-4, and several salts and derivatives with different active moieties are sold under the same name [1]. FDA's July 2026 review found no USP or National Formulary monograph for it and no approved product in any of the countries it checked [1].

Can a pharmacy compound it?

Under the federal compounding statute, a state-licensed pharmacy may compound with a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulks list [4]. TB-500 appears in none of the three categories of FDA's interim policy list for state-licensed pharmacies and physicians (updated May 14, 2026), and the policy of generally not acting against compounders does not cover it [2][4]. It is also absent from FDA's list for outsourcing facilities (updated March 21, 2025) [3]. It sits in the 'nominated but withdrawn' table on FDA's page about substances that may present significant safety risks, which holds substances previously in Category 2 whose nominators withdrew them; removal was not a safety finding [7]. FDA found no pharmacy marketing a compounded TB-500 product [1].

What happened in 2026

FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding TB-500 to the bulks list, against FDA staff's recommendation [8][5]. Staff had proposed not adding either the free base or the acetate, citing poor characterization, no human data and immunogenicity risk [1]. The vote is advice only, listing requires formal rulemaking, and TB-500 is not on the list [8][5].

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192; publication was scheduled for October 30, with comments due two weeks later) naming TB-500 among six peptides and covering the acetate form given by subcutaneous or intramuscular injection [5][6]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it where its conditions are met, such as a single active ingredient, a patient-specific prescription, and material from an FDA-registered manufacturer with a certificate of analysis [5][6]. The notice says it creates no rights and is not binding on HHS or the public [5].

Does Maryland law change this?

FDA's compounding rules apply to state-licensed pharmacies and physicians in every state, Maryland included. No Maryland-specific rule on TB-500 is established on this page.

What people on Reddit report

These accounts discuss whether this peptide can be legally obtained, how a recent announcement is being read, and whether adults should have access despite risk.

JustM700 · DiscussionZone

No formal FDA rule has been published yet. The PCAC review meeting is July 23-24, 2026 that's when formal implementation moves forward.

The poster says a recent announcement reclassified the peptide and that formal rules are still pending.

Read the source discussion

Dismal-Line257 · Biohackers

I don't think it's unreasonable for adults to have access to a legitimate, accurately labeled product even if there's some level of risk involved.

This commenter supports adult access to accurately labeled peptides while acknowledging risk and calling for testing.

Read the source discussion

Lucky_Ranger_833 · Biohackers

There are plenty of "legal" sources for this. They just say "For research purposes only."

This commenter argues that research-only labeling is used to sell peptides that are not clearly legal for personal use.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

Is it allowed in sport?

No. WADA's S2.3 names 'Thymosin-beta4 and its derivatives e.g. TB-500' and prohibits it at all times, in and out of competition; it is on the 2026 List and on the 2027 List [9][10].

What is known about TB-500 in people

FDA found no article in which TB-500 was given to a human, no approved dose and no human dosing study [1]. In an in-vitro scratch-wound test, TB-500 at 50 micrograms/mL did not induce wound closure in fibroblast cultures, while a shorter metabolite, N-acetylated LKKTE, showed activity [1]. Safety in humans is unknown: FDA found no nonclinical toxicity studies, no human pharmacokinetic data and no immunogenicity or aggregation studies, and its stated concern for injectable TB-500 is an immune reaction [1]. Its adverse-event database search through March 26, 2025 retrieved no TB-500 reports [1]. FDA also described a 40-year-old woman who used a 'research purposes only' BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, recurring when she retried it; because the product held two peptides, FDA said it could not tell whether either caused it [11].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. Under federal rules, does TB-500 clearly qualify for compounding in Maryland?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is TB-500 legal in Maryland?
Federal rules do not clearly allow it to be compounded. TB-500 is not FDA-approved, is absent from FDA's compounding lists, and FDA's policy of generally not acting against certain compounders does not cover it [1][2][3][4].
Is TB-500 FDA-approved?
No. FDA's July 2026 review found no approved drug containing TB-500 in the United States, Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].
Can a compounding pharmacy legally make TB-500?
A pharmacy may compound with a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on FDA's bulks list [4]. FDA found no USP or NF monograph and no approved drug containing TB-500 [1], and it is not on the bulks list [8][5].
Did the FDA advisory committee vote to allow TB-500?
FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding it to the bulks list, against staff's recommendation. The vote is non-binding advice and it is not on the list [8][5].
Does the HHS draft peptide policy make TB-500 legal?
No. It is a draft, non-binding statement that HHS does not intend to take enforcement action against certain licensed pharmacies, federal facilities and physicians that compound TB-500 acetate for injection under stated conditions; it creates no rights [5][6].
Is TB-500 banned in sport?
Yes under the WADA code. S2.3 names 'Thymosin-beta4 and its derivatives e.g. TB-500' and prohibits it at all times, in and out of competition, on the 2026 List and the 2027 List [9][10].
Show all 13 referencesHide references
Evidence overview for Is TB-500 Legal in Maryland? Federal Rules, State Law, and How to Get It